Literature DB >> 33244625

[Locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma significantly prolongs survival].

Panagiotis Balermpas1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33244625     DOI： 10.1007/s00066-020-01715-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

1.  Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment.

Authors:  Xiong Zou; Rui You; Huai Liu; Yu-Xiang He; Guo-Feng Xie; Zhi-Hai Xie; Ji-Bin Li; Rou Jiang; Li-Zhi Liu; Li Li; Meng-Xia Zhang; You-Ping Liu; Yi-Jun Hua; Ling Guo; Chao-Nan Qian; Hai-Qiang Mai; Dong-Ping Chen; Ying Luo; Liang-Fang Shen; Ming-Huang Hong; Ming-Yuan Chen
Journal:  Eur J Cancer       Date:  2017-04-07       Impact factor: 9.162

2.  Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A T C Chan; V Grégoire; J-L Lefebvre; L Licitra; E P Hui; S F Leung; E Felip
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

3.  Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.

Authors:  Chad G Rusthoven; Ryan M Lanning; Bernard L Jones; Arya Amini; Matthew Koshy; David J Sher; Daniel W Bowles; Jessica D McDermott; Antonio Jimeno; Sana D Karam
Journal:  Radiother Oncol       Date:  2017-04-19       Impact factor: 6.280

4.  Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.

Authors:  Li Zhang; Yan Huang; Shaodong Hong; Yunpeng Yang; Gengsheng Yu; Jun Jia; Peijian Peng; Xuan Wu; Qing Lin; Xuping Xi; Jiewen Peng; Mingjun Xu; Dongping Chen; Xiaojun Lu; Rensheng Wang; Xiaolong Cao; Xiaozhong Chen; Zhixiong Lin; Jianping Xiong; Qin Lin; Conghua Xie; Zhihua Li; Jianji Pan; Jingao Li; Shixiu Wu; Yingni Lian; Quanlie Yang; Chong Zhao
Journal:  Lancet       Date:  2016-08-23       Impact factor: 79.321

5.  Retrospective analysis of nasopharyngeal carcinoma treated during 1976-1985: late complications following megavoltage irradiation.

Authors:  A W Lee; S C Law; S H Ng; D K Chan; Y F Poon; W Foo; S Y Tung; F K Cheung; J H Ho
Journal:  Br J Radiol       Date:  1992-10       Impact factor: 3.039

Review 6.  Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.

Authors:  Matthias Guckenberger; Yolande Lievens; Angelique B Bouma; Laurence Collette; Andre Dekker; Nandita M deSouza; Anne-Marie C Dingemans; Beatrice Fournier; Coen Hurkmans; Frédéric E Lecouvet; Icro Meattini; Alejandra Méndez Romero; Umberto Ricardi; Nicola S Russell; Daniel H Schanne; Marta Scorsetti; Bertrand Tombal; Dirk Verellen; Christine Verfaillie; Piet Ost
Journal:  Lancet Oncol       Date:  2020-01       Impact factor: 41.316

7.  Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base.

Authors:  Zachary S Zumsteg; Michael Luu; Emi J Yoshida; Sungjin Kim; Mourad Tighiouart; John M David; Stephen L Shiao; Alain C Mita; Kevin S Scher; Eric J Sherman; Nancy Y Lee; Allen S Ho
Journal:  Cancer       Date:  2017-08-17       Impact factor: 6.921

8.  Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Roel Schlijper; Glenn S Bauman; Joanna Laba; X Melody Qu; Andrew Warner; Suresh Senan
Journal:  J Clin Oncol       Date:  2020-06-02       Impact factor: 44.544

9.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Authors:  Christopher C Parker; Nicholas D James; Christopher D Brawley; Noel W Clarke; Alex P Hoyle; Adnan Ali; Alastair W S Ritchie; Gerhardt Attard; Simon Chowdhury; William Cross; David P Dearnaley; Silke Gillessen; Clare Gilson; Robert J Jones; Ruth E Langley; Zafar I Malik; Malcolm D Mason; David Matheson; Robin Millman; J Martin Russell; George N Thalmann; Claire L Amos; Roberto Alonzi; Amit Bahl; Alison Birtle; Omar Din; Hassan Douis; Chinnamani Eswar; Joanna Gale; Melissa R Gannon; Sai Jonnada; Sara Khaksar; Jason F Lester; Joe M O'Sullivan; Omi A Parikh; Ian D Pedley; Delia M Pudney; Denise J Sheehan; Narayanan Nair Srihari; Anna T H Tran; Mahesh K B Parmar; Matthew R Sydes
Journal:  Lancet       Date:  2018-10-21       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.